{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:57:03Z","timestamp":1780329423002,"version":"3.54.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are associated with increased risk of bone loss due to chronic inflammation, nutritional deficiencies, and pharmacological treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this study was to evaluate bone mineral density (BMD) and selected bone turnover markers in IBD patients in clinical and endoscopic remission, treated with conventional therapy or anti-TNF-\u03b1 agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center study included 100 participants: 35 with CD, 37 with UC, and 28 age-matched healthy controls. Patients IBD participated in the study received conventional treatment or anti- TNF-\u03b1 therapy with ADA (adalimumab) or IFX (infliximab). IBD patients were in confirmed remission, without steroid use or comorbidities affecting bone metabolism. BMD was measured using dual-energy X-ray absorptiometry (DXA) at the lumbar spine (L2\u2013L4), the left femoral neck, and whole body. Serum levels of osteocalcin (OC), parathyroid hormone (PTH), sclerostin (SOST), fibroblast growth factor 23 (FGF23), Dickkopf-1 (DKK1), osteoprotegerin (OPG), and osteopontin (OPN) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The IBD group demonstrated a statistically significant higher OPN value (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.001) compared to the control group. Additionally, the total T-score revealed a significant difference between the groups (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.005), with the control group exhibiting the highest values. No significant differences were found in the levels of other bone density markers studied between the biologically treated group and the conventionally treated group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study indicates that patients with IBD are at risk of developing reduced bone mineral density and osteoporosis. While some bone turnover markers appear to normalize during remission, anti-TNF-\u03b1 treatment does not offer added benefits for bone metabolism compared to conventional therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1729584","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:04:17Z","timestamp":1770707057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone turnover markers in patients with inflammatory bowel disease in remission: a cross-sectional comparison of anti-TNF\u03b1 therapy with conventional maintenance therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"S.","family":"Jarmakiewicz-Czaja","sequence":"first","affiliation":[{"name":"Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzesz\u00f3w","place":["Rzesz\u00f3w, Poland"]},{"name":"University Center for Research and Development in Health Sciences","place":["Rzesz\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. R.","family":"Kiela","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Daniel Cracchiolo Institute for Pediatric Autoimmune Disease Research, Steele Children's Research Center, University of Arizona","place":["Tucson, AZ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Pi\u0105tek","sequence":"additional","affiliation":[{"name":"Chair and Department of Conservative Dentistry with Endodontics, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sokal-Dembowska","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Psychology, Collegium Medicum, University of Rzesz\u00f3w","place":["Rzesz\u00f3w, Poland"]},{"name":"University Center for Research and Development in Health Sciences","place":["Rzesz\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Guz","sequence":"additional","affiliation":[{"name":"Department of Electroradiology, Medical College, University of Rzeszow","place":["Rzeszow, Poland"]},{"name":"Department of Radiology, St. Jadwiga Queen Hospital No. 2","place":["Rzeszow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Radzki","sequence":"additional","affiliation":[{"name":"Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sztembis","sequence":"additional","affiliation":[{"name":"Endocrinology Clinic, Pro-Familia Specialist Hospital","place":["Rzesz\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Filip","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology with IBD Unit, St. Jadwiga Queen Hospital No. 2 Affiliated to the Medical College, University of Rzeszow","place":["Rzeszow, Poland"]},{"name":"Department of Internal Medicine, Medical College, University of Rzeszow","place":["Rzeszow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1053\/j.sempedsurg.2017.10.003","article-title":"Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes","volume":"26","author":"Yu","year":"2017","journal-title":"Semin Pediatr Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/med.21893","article-title":"Inflammatory bowel disease biomarkers","volume":"42","author":"Liu","year":"2022","journal-title":"Med Res Rev."},{"key":"B3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S1873-9946(14)50148-1","article-title":"Consensus guidelines of ECCO\/ESPGHAN on the medical management of pediatric Crohn's disease","volume":"8","author":"Ruemmele","year":"2014","journal-title":"J Crohns Colitis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.11005\/jbm.2018.25.4.213","article-title":"Osteoporosis and osteoporotic fractures in gastrointestinal disease","volume":"25","author":"Oh HJ Ryu","year":"2018","journal-title":"J Bone Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.4291\/wjgp.v6.i4.210","article-title":"Risk factors for osteoporosis in inflammatory bowel disease patients","volume":"6","author":"Lima","year":"2015","journal-title":"World J Gastrointest Pathophysiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1425610","DOI":"10.3389\/fimmu.2024.1425610","article-title":"Association between inflammatory bowel disease and osteoporosis in European and East Asian populations: exploring causality, mediation by nutritional status, and shared genetic architecture","volume":"15","author":"Kang","year":"2024","journal-title":"Front Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"110856","DOI":"10.1016\/j.humimm.2024.110856","article-title":"Inflammatory bowel disease and osteoporosis: common genetic effects, pleiotropy, and causality","volume":"85","author":"Hu","year":"2024","journal-title":"Hum Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/BOR.0b013e328356d212","article-title":"Effects of anti-tumor necrosis factor \u03b1 agents on bone","volume":"24","author":"Kawai","year":"2012","journal-title":"Curr Opin Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s00223-016-0114-x","article-title":"Short-term effects of TNF inhibitors on bone turnover markers and bone mineral density in rheumatoid arthritis","volume":"98","author":"Orsolini","year":"2016","journal-title":"Calcif Tissue Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.semarthrit.2008.04.004","article-title":"Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy","volume":"39","author":"Barnabe","year":"2009","journal-title":"Semin Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn's disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: part 1: diagnosis and medical management","volume":"11","author":"Gomoll\u00f3n","year":"2017","journal-title":"J Crohns Colitis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ecco-jcc\/jjac104","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management","volume":"17","author":"Harbord","year":"2023","journal-title":"J Crohns Colitis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jocd.2011.08.003","article-title":"BMD measurement and precision: a comparison of GE lunar prodigy and iDXA densitometers","volume":"15","author":"Krueger","year":"2012","journal-title":"J Clin Densitom."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.cgh.2024.02.009","article-title":"Defining endoscopic remission in Crohn's disease: MM-SES-CD and SES-CD thresholds associated with low risk of disease progression","volume":"22","author":"Narula","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000518131","article-title":"Assessment of endoscopic disease activity in ulcerative colitis: us simplicity the ultimate sophistication?","volume":"7","author":"Sharara","year":"2021","journal-title":"Inflamm Intest Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jocd.2019.07.009","article-title":"Bone health in patients with inflammatory bowel diseases","volume":"23","author":"Chedid","year":"2020","journal-title":"J Clin Densitom."},{"key":"B20","doi-asserted-by":"publisher","first-page":"G191","DOI":"10.1152\/ajpgi.00496.2010","article-title":"Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases","volume":"300","author":"Ghishan","year":"2011","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/gut.2006.117382","article-title":"Gut, inflammation and osteoporosis: basic and clinical concepts","volume":"57","author":"Tilg","year":"2008","journal-title":"Gut."},{"key":"B22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s00223-016-0192-9","article-title":"Bone metabolism and the c","volume":"99","author":"Krela-Kazmierczak","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1136\/gutjnl-2014-306947","article-title":"Bone marrow Th17 TNF\u03b1 cells induce osteoclast differentiation, and link bone destruction to IBD","volume":"64","author":"Ciucci","year":"2015","journal-title":"Gut."},{"key":"B24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12967-023-04449-0","article-title":"CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation through NF-\u03baB signaling pathway in ankylosing spondylitis in vitro","volume":"21","author":"Feng","year":"2023","journal-title":"J Transl Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","article-title":"Biological drug and drug delivery-mediated immunotherapy","volume":"11","author":"Xiao","year":"2021","journal-title":"Acta Pharm Sin B."},{"key":"B26","doi-asserted-by":"publisher","first-page":"100881","DOI":"10.1016\/j.xcrm.2022.100881","article-title":"Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases","volume":"4","author":"Guo","year":"2023","journal-title":"Cell Rep Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/MOG.0000000000000710","article-title":"Bone loss in patients with inflammatory bowel disease: cause, detection and treatment","volume":"37","author":"Bravenboer","year":"2021","journal-title":"Curr Opin Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"102422","DOI":"10.1016\/j.tice.2024.102422","article-title":"The role of TNF-\u03b1 in osteoporosis, bone repair and inflammatory bone diseases: a review","volume":"89","author":"Yao","year":"2024","journal-title":"Tissue Cell."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.3390\/jcm14113933","article-title":"Assessment of bone health in adult patients with inflammatory bowel disease: a single-center cohort study","volume":"14","author":"Cort\u00e9s-Berdonces","year":"2025","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1210\/jc.2014-4152","article-title":"Improvements in bone density and structure during anti-TNF-\u03b1 therapy in pediatric Crohn's disease","volume":"100","author":"Griffin","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1196\/annals.1346.055","article-title":"The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease","volume":"1068","author":"Pazianas","year":"2006","journal-title":"Ann N Y Acad Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/gut.2004.048298","article-title":"Osteopontin\/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response","volume":"54","author":"Sato","year":"2005","journal-title":"Gut."},{"key":"B33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.9738\/INTSURG-D-13-00160.1","article-title":"Plasma osteopontin predicts inflammatory bowel disease activities","volume":"100","author":"Komine-Aizawa","year":"2015","journal-title":"Int Surg."},{"key":"B34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/MCG.0b013e31802d6268","article-title":"High plasma osteopontin levels in patients with inflammatory bowel disease","volume":"41","author":"Mishima","year":"2007","journal-title":"J Clin Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1093\/rheumatology\/ken385","article-title":"Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis","volume":"47","author":"Choi","year":"2008","journal-title":"Rheumatology (Oxford)."},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00774-020-01162-6","article-title":"Osteoclast differentiation by RANKL and OPG signaling pathways","volume":"39","author":"Udagawa","year":"2021","journal-title":"J Bone Miner Metab."},{"key":"B37","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1007\/s10620-013-2851-2","article-title":"Osteoprotegerin exerts its pro-inflammatory effects through nuclear factor-\u03baB activation","volume":"58","author":"Nahidi","year":"2013","journal-title":"Dig Dis Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/cells11010132","article-title":"Regulation of TNF-induced osteoclast differentiation","volume":"11","author":"Yao","year":"2021","journal-title":"Cells."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.bone.2004.07.004","article-title":"TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis","volume":"35","author":"Saidenberg-Kermanac'h","year":"2004","journal-title":"Bone"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.3390\/jcm11071840","article-title":"Bone alterations in inflammatory bowel diseases: role of osteoprotegerin","volume":"11","author":"Priadko","year":"2022","journal-title":"J Clin Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/01.MIB.0000164015.60795.ca","article-title":"Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study","volume":"11","author":"Bernstein","year":"2005","journal-title":"Inflamm Bowel Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.17219\/acem\/75675","article-title":"Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases","volume":"27","author":"Krela-Kazmierczak","year":"2018","journal-title":"Adv Clin Exp Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1136\/gut.2004.044370","article-title":"The RANKL\/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss","volume":"54","author":"Moschen","year":"2005","journal-title":"Gut."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/ibd.20234","article-title":"Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy","volume":"13","author":"Miheller","year":"2007","journal-title":"Inflamm Bowel Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s13312-019-1649-5","article-title":"Correlation of Dickkopf-1 with inflammation in Crohn disease","volume":"56","author":"Kim","year":"2019","journal-title":"Indian Pediatr."},{"key":"B46","doi-asserted-by":"publisher","first-page":"132","DOI":"10.20524\/aog.2023.0785","article-title":"Signaling pathways associated with bone loss in inflammatory bowel disease","volume":"36","author":"Palatianou","year":"2023","journal-title":"Ann Gastroenterol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1523967","DOI":"10.3389\/fcell.2024.1523967","article-title":"Corrigendum: Advances in understanding the regulation of pluripotency fate transition in embryonic stem cells","volume":"12","author":"Jia YK Yu","year":"2024","journal-title":"Front Cell Dev Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1562764","DOI":"10.3389\/fcell.2025.1562764","article-title":"Localized sclerostin accumulation in osteocyte lacunar-canalicular system is associated with cortical bone microstructural alterations and bone fragility in db\/db male mice","volume":"13","author":"Wu","year":"2025","journal-title":"Front Cell Dev Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/MEG.0000000000000719","article-title":"A 1-year prospective study of the effect of infliximab on bone metabolism in inflammatory bowel disease patients","volume":"28","author":"Veerappan","year":"2016","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00198-022-06523-7","article-title":"Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders","volume":"34","author":"Marini","year":"2023","journal-title":"Osteoporos Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/bs.acc.2020.06.005","article-title":"Parathyroid hormone","volume":"101","author":"Leung","year":"2021","journal-title":"Adv Clin Chem."},{"key":"B52","doi-asserted-by":"publisher","first-page":"dgaa579","DOI":"10.1210\/clinem\/dgaa579","article-title":"Parathyroid hormone and bone mineral density: a Mendelian randomization study","volume":"105","author":"Qu","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B53","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.autrev.2017.01.014","article-title":"Effects of targeted therapies on the bone in arthritides","volume":"16","author":"Szentp\u00e9tery","year":"2017","journal-title":"Autoimmun Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","article-title":"Effects of 1-year anti-TNF-\u03b1 therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis","volume":"39","author":"Guly\u00e1s","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00359.2016","article-title":"Ironing out the cross talk between FGF23 and inflammation","volume":"312","author":"David","year":"2017","journal-title":"Am J Physiol Renal Physiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1471-230X-12-44","article-title":"Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease","volume":"12","author":"El-Hodhod","year":"2012","journal-title":"BMC Gastroenterol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jocd.2013.03.019","article-title":"Lower fibroblast growth factor 23 levels in young adults with Crohn disease as a possible secondary compensatory effect on the disturbance of bone and mineral metabolism","volume":"17","author":"Oikonomou","year":"2014","journal-title":"J Clin Densitom."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08977194.2023.2274579","article-title":"Fibroblast growth factor 23 and its role in bone diseases","volume":"42","author":"Jurina","year":"2024","journal-title":"Growth Factors."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.3390\/ijms23052500","article-title":"Fibroblast growth factor 23 and osteoporosis: evidence from bench to bedside","volume":"23","author":"Sirikul","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0337408","DOI":"10.1371\/journal.pone.0337408","article-title":"multi-mineral intervention to improve disease-related and mechanistic biomarkers in ulcerative colitis patients: results from a randomized trial","volume":"20","author":"Aslam","year":"2025","journal-title":"PLoS One."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1729584\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:04:19Z","timestamp":1770707059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1729584\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":60,"alternative-id":["10.3389\/fmed.2026.1729584"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1729584","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"article-number":"1729584"}}